An Open-Label, Double-Treatment Group Study to Evaluate the Efficacy and Safety of Human Allogeneic Bone-Marrow- Derived Mesenchymal Stromal Cell Product StromaForte Compared With Hyaluronic Acid for the Treatment of Knee Osteoarthritis

Inclusion Criteria: * Willing and able to provide written informed consent and comply with all procedures required by the protocol. * Aged ≥ 18 years at the time of signing the informed consent form. * Diagnosed with knee osteoarthritis (OA) based on the criteria established by the American College of Rheumatology, confirmed through radiological images no older than three months. * Grade I to IV osteoarthritis on the Kellgren-Lawrence radiological classification scale. * Joint pain during activity as assessed by the Visual Analogue Scale (VAS) of ≥ 40 at the time of screening * Body Mass Index (BMI) between ≥ 18.5 to ≤ 35.0 kg/m2 Exclusion Criteria: * Unwilling or unable to perform any of the assessments required by the protocol. * Mechanically unstable knee due to the presence of a complete anterior cruciate ligament, posterior cruciate ligament, medial collateral ligament and/or posterolateral corner tear. * Varus or valgus malalignment \>5 degrees as measured by 4-foot standing antero-posterior radiographs. * History of subtotal medial or lateral meniscectomy performed less than 9 months ago. * History of septic arthritis in the targeted knee. * History of infectious or inflammatory joint disorders or suspected infective or inflammatory joint disease. * Systemic or intra-articular injection of corticosteroids in any joint within 3 months before screening. * Immunosuppression due to illness or medication including but not limited to high dose corticosteroids, calcineurin…